28226266|t|Parallel artificial liquid membrane extraction of new psychoactive substances in plasma and whole blood
28226266|a|Parallel artificial liquid membrane extraction (PALME) was combined with ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) and the potential for screening of new psychoactive substances (NPS) was investigated for the first time. PALME was performed in 96- well format comprising a donor plate, a supported liquid membrane (SLM), and an acceptor plate. Uncharged NPS were extracted from plasma or whole blood, across an organic SLM, and into an aqueous acceptor solution, facilitated by a pH gradient. MDAI (5,6-methylenedioxy-2-aminoindane), methylone, PFA (para-fluoroamphetamine), mCPP (meta-chlorophenylpiperazine), pentedrone, methoxetamine, MDPV (methylenedioxypyrovalerone), ethylphenidate, 2C-E (2,5-dimethoxy-4-ethylphenethylamine), bromo-dragonfly, and AH-7921 (3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide) were selected as representative NPS. Optimization of operational parameters was necessary as the NPS were novel to PALME, and because PALME was performed from whole blood for the very first time. In the PALME method developed for plasma, NPS were extracted from a 250μL alkalized donor solution consisting of 125μL plasma sample, 115μL 40mM NaOH, and 10μL internal standard. In the PALME method from whole blood, the 250μL alkalized donor solution consisted of 100μL whole blood, 50μL deionized water, 75μL 80mM NaOH, and 25μL internal standard. In both method s, extraction was accomplished across an SLM of 5μL dodecyl acetate with 1% trioctylamine (w/w), and further into an acidic acceptor solution of 50μL 20mM formic acid. The extraction was promoted by agitation at 900 rpm and was carried out for 120min. Method validation was performed and the following parameters were considered: linearity, limits of quantification (LOQ), intra - and inter - day precision, accuracy, extraction recoveries, carry - over, and matrix effects. The validation results were in accordance with FDA guidelines.
28226266	0	8	Parallel	T082	C1254362
28226266	9	35	artificial liquid membrane	T074	C0025256
28226266	36	46	extraction	T059	C0684295
28226266	54	77	psychoactive substances	T121,T131	C0682880
28226266	81	87	plasma	T031	C0032105
28226266	92	103	whole blood	T031	C0370231
28226266	104	112	Parallel	T082	C1254362
28226266	113	139	artificial liquid membrane	T074	C0025256
28226266	140	150	extraction	T059	C0684295
28226266	152	157	PALME	T059	C0684295
28226266	163	171	combined	T080	C0205195
28226266	177	239	ultra-high performance liquid chromatography-mass spectrometry	T059	C4053724
28226266	241	249	UHPLC-MS	T059	C4053724
28226266	259	268	potential	T080	C3245505
28226266	273	282	screening	T058	C0220908
28226266	290	313	psychoactive substances	T121,T131	C0682880
28226266	315	318	NPS	T121,T131	C0682880
28226266	324	336	investigated	T169	C1292732
28226266	357	362	PALME	T059	C0684295
28226266	367	376	performed	T169	C0884358
28226266	384	388	well	T082	C4283957
28226266	396	406	comprising	T052	C2700400
28226266	409	414	donor	T201	C3263710
28226266	415	420	plate	T075	C1709027
28226266	424	449	supported liquid membrane	T074	C0025256
28226266	451	454	SLM	T074	C0025256
28226266	464	472	acceptor	T078	C1548601
28226266	473	478	plate	T075	C1709027
28226266	480	489	Uncharged	T080	C4287836
28226266	490	493	NPS	T121,T131	C0682880
28226266	499	508	extracted	T059	C0684295
28226266	514	520	plasma	T031	C0032105
28226266	524	535	whole blood	T031	C0370231
28226266	547	554	organic	T080	C0747055
28226266	555	558	SLM	T074	C0025256
28226266	572	579	aqueous	T080	C0599956
28226266	580	588	acceptor	T078	C1548601
28226266	589	597	solution	T167	C0037633
28226266	616	627	pH gradient	T081	C1138565
28226266	629	633	MDAI	T109	C0081183
28226266	635	667	5,6-methylenedioxy-2-aminoindane	T109	C0081183
28226266	670	679	methylone	T109	C0910385
28226266	681	684	PFA	T109,T121	C0048271
28226266	686	708	para-fluoroamphetamine	T109,T121	C0048271
28226266	711	715	mCPP	T109,T121	C0044170
28226266	717	744	meta-chlorophenylpiperazine	T109,T121	C0044170
28226266	747	757	pentedrone	T109,T121	C3492415
28226266	759	772	methoxetamine	T109,T121	C3253535
28226266	774	778	MDPV	T109,T121	C3532997
28226266	780	806	methylenedioxypyrovalerone	T109,T121	C3532997
28226266	809	823	ethylphenidate	T109	C0622071
28226266	825	829	2C-E	T121	C1254351
28226266	831	866	2,5-dimethoxy-4-ethylphenethylamine	T121	C1254351
28226266	869	884	bromo-dragonfly	T109	C2715878
28226266	890	897	AH-7921	T109,T121	C0051008
28226266	899	960	3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide	T109,T121	C0051008
28226266	979	993	representative	T052	C1882932
28226266	994	997	NPS	T121,T131	C0682880
28226266	999	1011	Optimization	T052	C2698650
28226266	1015	1026	operational	T052	C3241922
28226266	1027	1037	parameters	T077	C0549193
28226266	1059	1062	NPS	T121,T131	C0682880
28226266	1077	1082	PALME	T059	C0684295
28226266	1096	1101	PALME	T059	C0684295
28226266	1106	1115	performed	T169	C0884358
28226266	1121	1132	whole blood	T031	C0370231
28226266	1165	1170	PALME	T059	C0684295
28226266	1171	1177	method	T170	C0025663
28226266	1178	1187	developed	T169	C1527148
28226266	1192	1198	plasma	T031	C0032105
28226266	1200	1203	NPS	T121,T131	C0682880
28226266	1209	1218	extracted	T059	C0684295
28226266	1232	1241	alkalized	T059	C1551382
28226266	1242	1247	donor	T201	C3263710
28226266	1248	1256	solution	T167	C0037633
28226266	1277	1283	plasma	T031	C0032105
28226266	1284	1290	sample	T167	C0370003
28226266	1303	1307	NaOH	T131,T197	C0037517
28226266	1318	1335	internal standard	T081	C0034925
28226266	1344	1349	PALME	T059	C0684295
28226266	1350	1356	method	T170	C0025663
28226266	1362	1373	whole blood	T031	C0370231
28226266	1385	1394	alkalized	T059	C1551382
28226266	1395	1400	donor	T201	C3263710
28226266	1401	1409	solution	T167	C0037633
28226266	1429	1440	whole blood	T031	C0370231
28226266	1447	1462	deionized water	T121	C3199728
28226266	1474	1478	NaOH	T131,T197	C0037517
28226266	1489	1506	internal standard	T081	C0034925
28226266	1516	1522	method	T170	C0025663
28226266	1526	1536	extraction	T059	C0684295
28226266	1564	1567	SLM	T074	C0025256
28226266	1575	1590	dodecyl acetate	T109,T130	C0623374
28226266	1599	1612	trioctylamine	T109,T121	C0076985
28226266	1640	1646	acidic	T103	C0001128
28226266	1647	1655	acceptor	T078	C1548601
28226266	1656	1664	solution	T167	C0037633
28226266	1678	1689	formic acid	T109,T121,T130	C0016576
28226266	1695	1705	extraction	T059	C0684295
28226266	1710	1718	promoted	T052	C0033414
28226266	1722	1731	agitation	T052	C1883171
28226266	1739	1742	rpm	T081	C0582523
28226266	1775	1781	Method	T170	C0025663
28226266	1782	1792	validation	T062	C1519941
28226266	1797	1806	performed	T169	C0884358
28226266	1815	1824	following	T079	C0332282
28226266	1825	1835	parameters	T077	C0549193
28226266	1841	1851	considered	T078	C0750591
28226266	1864	1888	limits of quantification	T081	C2718050
28226266	1890	1893	LOQ	T081	C2718050
28226266	1896	1901	intra	T079	C0347985
28226266	1908	1913	inter	T079	C1548610
28226266	1916	1929	day precision	T078	C1561539
28226266	1931	1939	accuracy	T080	C0443131
28226266	1941	1951	extraction	T059	C0684295
28226266	1952	1962	recoveries	T052	C0237820
28226266	1964	1969	carry	T052	C0206243
28226266	1972	1976	over	T082	C0205136
28226266	1982	1988	matrix	T109,T121	C4050026
28226266	1989	1996	effects	T080	C1280500
28226266	2002	2020	validation results	T033	C0683954
28226266	2045	2048	FDA	T093	C0041714
28226266	2049	2059	guidelines	T170	C0162791